SCHEMBL8549265

SCHEMBL8549265

O=CC(c1ccc(F)cc1)c1ccccc1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.38
GABRB2 P47870 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
TSHR P16473 1/20 0.35
HPGD P15428 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
MAPT P10636 2/20 0.35
HTT P42858 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
ALOX12 P18054 1/20 0.35
KMT2A Q03164 1/20 0.35
TRIM24 O15164 1/20 0.34
TRIM33 Q9UPN9 1/20 0.34
DHODH Q02127 1/20 0.34
LMNA P02545 2/20 0.33
TACR1 P25103 2/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8377 0.85 GABRA1 (0.43) GABRA1GABRB2TSHRHPGDSMN1; SMN2
SCHEMBL7260358 0.85 GABRA1 (0.37) GABRA1GABRB2MAOAMAOBTSHR
SCHEMBL26999259 0.83 TSHR (0.39) GABRA1GABRB2MAOAMAOBTSHR
SCHEMBL26999257 0.83 ACP3 (0.41) GABRA1GABRB2TSHRHPGDALDH1A1
SCHEMBL14125895 0.83 GABRA1 (0.42) GABRA1GABRB2TSHRHPGDSMN1; SMN2
SCHEMBL6631529 0.83 GABRA1 (0.38) GABRA1GABRB2TSHRHPGDSMN1; SMN2
SCHEMBL9363514 0.82 IDO1 (0.36) HPGDSMN1; SMN2MAPTHTTNPSR1
SCHEMBL15528140 0.82 HDAC4 (0.41) GABRA1GABRB2TSHRHPGDMAPT
SCHEMBL26999364 0.81 NFE2L2 (0.31) HPGDSMN1; SMN2HTTNPSR1LMNA
SCHEMBL3958574 0.80 TYR (0.39) SMN1; SMN2MAPTHTTLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873315-B2 Chiral n-heterocyclic phosphorodiamidic acids (NHPAS) and derivatives as novel Brønsted acid catalysts THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) 2024-01-16 US disclosed
EP-0825989-A1 SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1998-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873315-B2 Chiral n-heterocyclic phosphorodiamidic acids (NHPAS) and derivatives as novel Brønsted acid catalysts ELANE, PNKP, SERPINB1 GABRA1 1124/4885GABRB2 2338/4885MAOA 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.